Investment
Features
FeesSafety
Academy
More
Pluang+

Wintrust Financial posts strong Q2 2026 profit with solid asset quality, maintaining a soft buy rating.

Analyst Insights
18 Sep 2026
Seeking Alpha
View Source
Bullish
Wintrust Financial posts strong Q2 2026 profit with solid asset quality, maintaining a soft buy rating.

Wintrust Financial Corporation reported robust growth in Q2 2026, with deposits rising to $61.14 billion and loans increasing to $55.25 billion. The company showed strong asset quality and low exposure to brokered deposits, alongside notable premium finance receivables. Both net interest income and non-interest income increased, driving net profit to $225.3 million. Despite trading at a fair valuation with a P/E of 11.4 and P/TBV of 1.61, the company’s superior returns and credit quality support its soft buy rating.

Wintrust Financial's recent performance is presented here alongside Pluang's Financials sector data. As of Sep 18, 2026 19:02 WIB, 27 of 81 priced Financials-sector US stocks rose while 48 fell. Notable movers include BBVA at USD 28.20 with a -2.19% change and 100% buy order activity, Barclays PLC at USD 25.10 with a -2.11% change and 66% buy order activity, and Deutsche Bank AG at USD 38.25 with a -2.05% change and 100% buy order activity.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token hits new all-time high after Hyperliquid enables manual USDC/USDT borrowing with HYPE and Bitcoin collateral.

HYPE token surged 10.5% to $91.20, reaching a new all-time high of $92.56 after Hyperliquid launched manual borrowing of USDC and USDT using HYPE and Bitcoin as collateral. The platform offers a 65% loan-to-value ratio for HYPE, higher than Bitcoin's...

Market News
Bullish
4 hours ago
CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech hires Mercator for independent report on fluorspar project in Kentucky, advancing critical mineral exploration.

CleanTech Vanadium Mining Corp. has engaged Mercator Geological Services to prepare an independent technical report on its Campbell-Crotser fluorspar project in Kentucky, following National Instrument 43-101 standards. The report will detail geology,...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App